[(R)-1-methyl-2-(3-methyl-pyrrolidin-1-yl)-2-oxo-ethyl]carbamic acid tert-butyl ester | 1415969-11-7

• 英文名称: [(R)-1-methyl-2-(3-methyl-pyrrolidin-1-yl)-2-oxo-ethyl]carbamic acid tert-butyl ester
• CAS: 1415969-11-7
• 化学式: C₁₃H₂₄N₂O₃
• 分子量: 256.345
• InChiKey: KFFRYTCAZDKVFX-QVDQXJPCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.77
• 重原子数：
  18.0
• 可旋转键数：
  2.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  58.64
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  [(R)-1-methyl-2-(3-methyl-pyrrolidin-1-yl)-2-oxo-ethyl]carbamic acid tert-butyl ester 在 乙酰氯 作用下， 以 甲醇 为溶剂， 反应 18.0h， 以0.18 g的产率得到(R)-1-methyl-2-(3-methyl-pyrrolidin-1-yl)-2-oxo-ethyl-ammonium chloride
  参考文献：
  名称：

  3-Amido Pyrrolopyrazine JAK Kinase Inhibitors: Development of a JAK3 vs JAK1 Selective Inhibitor and Evaluation in Cellular and in Vivo Models

  摘要：

  The Janus kinases (JAKs) are involved in multiple signaling networks relevant to inflammatory diseases, and inhibition of one or more members of this class may modulate disease activity or progression. We optimized a new inhibitor scaffold, 3-amido-5-cyclopropylpyrrolopyrazines, to a potent example with reasonable kinome selectivity, including selectivity for JAK3 versus JAK1, and good biopharmaceutical properties. Evaluation of this analogue in cellular and in vivo models confirmed functional selectivity for modulation of a JAK3/JAK1-dependent IL-2 stimulated pathway over a JAK1/JAK2/Tyk2-dependent IL-6 stimulated pathway.

  DOI：

  10.1021/jm301646k
• 作为产物：
  描述：

  BOC-D-丙氨酸 、 3-氰基吡咯烷盐酸盐 在 1-羟基苯并三唑一水物 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以100%的产率得到[(R)-1-methyl-2-(3-methyl-pyrrolidin-1-yl)-2-oxo-ethyl]carbamic acid tert-butyl ester
  参考文献：
  名称：

  3-Amido Pyrrolopyrazine JAK Kinase Inhibitors: Development of a JAK3 vs JAK1 Selective Inhibitor and Evaluation in Cellular and in Vivo Models

  摘要：

  The Janus kinases (JAKs) are involved in multiple signaling networks relevant to inflammatory diseases, and inhibition of one or more members of this class may modulate disease activity or progression. We optimized a new inhibitor scaffold, 3-amido-5-cyclopropylpyrrolopyrazines, to a potent example with reasonable kinome selectivity, including selectivity for JAK3 versus JAK1, and good biopharmaceutical properties. Evaluation of this analogue in cellular and in vivo models confirmed functional selectivity for modulation of a JAK3/JAK1-dependent IL-2 stimulated pathway over a JAK1/JAK2/Tyk2-dependent IL-6 stimulated pathway.

  DOI：

  10.1021/jm301646k